Showing results (311-320 of 338) with videos related to
Sort By:
Pageof 34
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2024
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung CancerJames Chih-Hsin Yang, Dae Ho Lee, Jong-Seok Lee, et al.Cancer Immunology, Immunotherapy : CII|October 9, 2024
Biomarker role of thyroid irAE and PD-L1 positivity in predicting PD-1 blockade efficacy in patients with non-small cell lung cancerHye In Kim, Won Gu Kim, Mijin Kim, et al.Nature Cancer|May 1, 2026
Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trialIgnacio Melero, Bernhard Reis, Corinne Rusterholz, et al.The Lancet. Oncology|October 8, 2019
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 studyMyung-Ju Ahn, Ji-Youn Han, Ki Hyeong Lee, et al.International Journal of Hematology|October 16, 2012
Waldeyer's ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal? A study by the Consortium for Improving Survival of Lymphoma (CISL)Sung Yong Oh, Won Seog Kim, Jin Seok Kim, et al.Diabetes, Obesity & Metabolism|December 28, 2016
Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study)Chang Ho Ahn, Kyung Ah Han, Jae Myung Yu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 30, 2025
Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLCTimothy F Burns, Natraj Reddy Ammakkanavar, Antoine Hollebecque, et al.Cancer Science|September 14, 2010
Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) studySung Yong Oh, Won Seog Kim, Jin Seok Kim, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 26, 2021
Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive CohortRafal Dziadziuszko, Tony Mok, Solange Peters, et al.The Lancet. Oncology|June 12, 2021
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 studyJustin F Gainor, Giuseppe Curigliano, Dong-Wan Kim, et al.Pageof 34